Étude multicentrique de phase III menée sans insu, avec répartition aléatoire, comparant le traitement d’association par le vénétoclax et la dexaméthasone au traitement d’association par la pomalidomide et la dexaméthasone, chez des sujets atteints d’un myélome multiple réfractaire ou récidivant qui présente une translocation t(11:14)

Phase III

Rechute et réfractaire

Thérapie ciblée

Adultes

Documented diagnosis of multiple myeloma (MM) based on standard IMWG criteria.
Measurable disease at screening as defined per protocol.
Has received at least 2 prior lines of therapy as described in the protocol.
Has had documented disease progression on or within 60 days after completion of the last therapy.
Has received at least 2 consecutive cycles of lenalidomide and be relapsed/refractory to lenalidomide, as defined per protocol.
Has received at least 2 consecutive cycles of a proteasome inhibitor (PI).
Has MM positive for t(11;14).
An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
Laboratory values (liver, kidney and hematology laboratory values) that meet criteria as described per protocol.

History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or pomalidomide.
History of other active malignancies, including myelodysplastic syndromes (MDS), within the past 3 years (exceptions described in the protocol).
Evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant (SCT).
Prior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks prior to randomization; or autologous SCT within 12 weeks prior to randomization.
Known central nervous system involvement of MM.
Concurrent conditions as listed in the protocol.

Hôtel-Dieu de Lévis

Investigateur(trice) principal(e): Danièle Marceau
Pierre_Bedard@ssss.gouv.qc.ca